ClinicalTrials.gg

Program

Enavogliflozin

Also written as “DWP16001”, “DWP16001 0.3mg” and “DWP16001 Amg”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetic Nephropathies, led by Daewoong Pharmaceutical.

Furthest: phase 3, since Nov 12, 202025 company-led studies, 8 open or runningNext primary completion: Nov 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Daewoong Pharmaceutical258 open or runningphase 3since Nov 12, 2020Nov 29, 2017Nov 2027phase 3 · NCT07619833

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 10 studies since Nov 29, 2017.

  1. Jan 9, 20222 phase 3 studies in Diabetes Mellitus, Type 2NCT05376969, NCT05376930
  2. Jun 8, 2022Phase 1 study in HealthyNCT05414591 · 38 enrolled · Korea, Republic of
  3. Jul 5, 2022Phase 1 study in Healthy VolunteersNCT05465668 · 43 enrolled · Korea, Republic of
  4. Jul 12, 2022Phase 3 study in Diabetes Mellitus, Type 2NCT05466643 · 240 planned · Korea, Republic of
  5. Aug 12, 2022Phase 1 study in HealthyNCT05500898 · 53 enrolled
  6. Aug 16, 2022Phase 3 study in Diabetes MellitusNCT05505994 · 340 enrolled · China
  7. Jan 17, 2023Phase 1 study in Diabetes Mellitus, Type 2NCT05737771 · 40 enrolled · Korea, Republic of
  8. Feb 8, 2023Phase 1 study in Diabetes Mellitus, Type 2NCT05747664 · 24 planned · Korea, Republic of
  9. Mar 21, 2023Phase 1 study in HealthyNCT05797922 · 32 planned · Korea, Republic of
  10. Nov 10, 2023Phase 3 study in Diabetes Mellitus, Type 2NCT06141980 · 134 planned
  11. Sep 10, 2024Phase 3 study in Type 2 Diabetic NephropathyNCT06606093 · 348 planned · Korea, Republic of
  12. Oct 11, 2024Phase 1 study in HealthyNCT06644404 · 34 planned · Korea, Republic of
  13. Jul 29, 2025Phase 1 study in HealthyNCT07213310 · 18 enrolled · South Korea
  14. May 26, 2026Phase 3 study in Diabetes Mellitus, Type 2NCT07619833 · 510 planned · South Korea

Ahead

  1. Nov 2027Primary completion: phase 3 study in Diabetes Mellitus, Type 2NCT07619833

TargetBeta

SLC5A2 →read by rule
“The primary objective of this study is to investigate the effect of enavogliflozin, an Sodium-glucose transporter 2 (SGLT2) inhibitor, compared with placebo on left ventricular diastolic function in patients with nonobstructive hypertrophic cardiomyopathy.”study text, by rule · the study

Other programs on SLC5A2

ProgramCompanyFurthest phaseStudies
empagliflozinruleBoehringer Ingelheimphase 4142
dapagliflozinAstraZenecaphase 4133
ertugliflozinruleMerckphase 422
vicadrostatBoehringer Ingelheimphase 316
Empagliflozin/LinagliptinruleHumanis Saglık Anonim Sirketiphase 12

Studies

All 25 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07619833Diabetes Mellitus, Type 2 · South Korea3Not yet recruitingNov 2027510
NCT07213310Healthy · South Korea1CompletedJan 7, 202618
NCT06644404Healthy · Korea, Republic of1Not yet recruitingDec 3, 202434
NCT06606093Type 2 Diabetic Nephropathy · Korea, Republic of3Not yet recruitingSep 1, 2026348
NCT06141980Diabetes Mellitus, Type 23Not yet recruitingSep 2025134
NCT05797922Healthy · Korea, Republic of1RecruitingMay 31, 202332
NCT05747664Diabetes Mellitus, Type 2 · Korea, Republic of1RecruitingApr 30, 202424
NCT05737771Diabetes Mellitus, Type 2 · Korea, Republic of1UNKNOWNMar 31, 202340
NCT05505994Diabetes Mellitus · China3Active, not recruitingFeb 26, 2024340
NCT05500898Healthy1UNKNOWNOct 31, 202253
NCT05466643Diabetes Mellitus, Type 2 · Korea, Republic of3RecruitingSep 30, 2024240
NCT05465668Healthy Volunteers · Korea, Republic of1CompletedAug 16, 202243
NCT05414591Healthy · Korea, Republic of1CompletedAug 1, 202138
NCT05321732Healthy Volunteers · Korea, Republic of1UNKNOWNAug 202224
NCT05207176Healthy1UNKNOWNApr 8, 202224
NCT05376969Diabetes Mellitus, Type 2 · Korea, Republic of3CompletedMay 16, 2022159
NCT05376930Diabetes Mellitus, Type 2 · Korea, Republic of3CompletedMay 31, 202263
NCT05192395Healthy · Korea, Republic of1CompletedMay 24, 202237
NCT04654390Diabetes Mellitus, Type 2 · Korea, Republic of3CompletedDec 17, 2021270
NCT04632862Diabetes Mellitus, Type 2 · Korea, Republic of3CompletedNov 25, 2021140
NCT04343547Healthy · Korea, Republic of1UNKNOWNJul 202034
NCT04221399Type2 Diabetes1UNKNOWNAug 202035
NCT04064073Healthy · Korea, Republic of1CompletedNov 20, 201934
NCT04014023Diabetes Mellitus, Type 2 · Korea, Republic of2UNKNOWNMar 2020196
NCT03364985Healthy · Korea, Republic of1CompletedMay 21, 2019123

How it is read

Names in the registry

  • “DWP16001”, 18 entries
  • “DWP16001 0.3mg”, 3 entries
  • “DWP16001 Amg”, 2 entries
  • “DWP16001 0.3 mg”, 1 entry
  • “DWP16001 Drug A”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.